DistantNews
Support us
Founder's Will Resurfaces, Yuhan Corp. Bets on AI
๐Ÿ‡ฐ๐Ÿ‡ท South Korea /Economy & Trade

Founder's Will Resurfaces, Yuhan Corp. Bets on AI

From Chosun Ilbo · () Korean

Translated from Korean, summarized and contextualized by DistantNews.

At a glance

News Sources not specified Context piece
  • Yuhan Corporation's late founder, Yu Il-han, left behind a will that has resurfaced, emphasizing his commitment to social contribution.
  • His will, read out posthumously, details the donation of his 149,401 shares to Korean society and trusts.
  • The company is now leveraging AI in its business strategy, following the founder's legacy of innovation and social responsibility.

The spirit of the late founder of Yuhan Corporation, Yu Il-han, echoed through the company's former headquarters in Seoul, as his will was read out, emphasizing his enduring commitment to social contribution. The will, delivered as if the founder himself were speaking, detailed the donation of his 149,401 shares to Korean society and trusts.

Yu Il-han, who passed away in 1971, had previously allocated assets to his granddaughter and daughter, ensuring their self-sufficiency. Now, his posthumous message highlights a continued dedication to philanthropy, with his shares earmarked for societal benefit.

In a move that bridges the past with the future, Yuhan Corporation is reportedly embracing artificial intelligence in its business strategies. This forward-looking approach, coupled with the founder's legacy of innovation and social responsibility, positions the company to navigate the evolving landscape of the pharmaceutical industry.

I donate my 149,401 shares to Korean society and trusts. My son Il-sun, having graduated from university, should live independently.

โ€” Yu Il-han (founder)The late founder's will, read out at the former Yuhan Corporation headquarters.
DistantNews Editorial

Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.